Patents Assigned to Pharma Pacific Pty Ltd.
-
Publication number: 20080193412Abstract: A method for enhancing the immune response to an antigen or vaccine comprising administering an effective amount of a Th1 stimulatory cytokine, preferably interferon, oromucosally at substantially the same time as administration of an effective amount of an antigen or vaccine.Type: ApplicationFiled: June 13, 2005Publication date: August 14, 2008Applicant: PHARMA PACIFIC PTY LTD.Inventor: Michael Tovey
-
Publication number: 20070226815Abstract: The present invention relates to identification of a gene upregulated by interferon-a administration corresponding to the cDNA sequence set forth in SEQ. ID. NO. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same geneis also envisaged.Type: ApplicationFiled: October 27, 2006Publication date: September 27, 2007Applicant: Pharma Pacific Pty Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Tovey
-
Patent number: 7244818Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ ID NO: 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-a and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.Type: GrantFiled: December 13, 2000Date of Patent: July 17, 2007Assignee: Pharma Pacific Pty. Ltd.Inventors: Jean-François Meritet, Michel Dron, Michael Gerard Tovey
-
Publication number: 20070117145Abstract: The present disclosure relates to identification of previously known genes as being genes upregulated by interferon-? administration, in particular the human genes corresponding to the cDNA sequence in GenBank designated g4758303, g5453897, g4505186, g2366751, g33917, g4504962, g3978516, g5924396, g4505656, g1504007, g3702446, g4001802, g292289, g4557226, g4507646 and g4507170. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor.Type: ApplicationFiled: December 22, 2006Publication date: May 24, 2007Applicant: Pharma Pacific Pty. Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Tovey
-
Publication number: 20060275298Abstract: Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition or prevention of auto immune diseases.Type: ApplicationFiled: August 14, 2006Publication date: December 7, 2006Applicant: Pharma Pacific Pty. Ltd.Inventor: Michael Tovey
-
Publication number: 20060275258Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.Type: ApplicationFiled: August 14, 2006Publication date: December 7, 2006Applicant: Pharma Pacific Pty. Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Gerard Tovey
-
Publication number: 20060141580Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequence set forth in SEQ. ID. NO. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.Type: ApplicationFiled: January 19, 2006Publication date: June 29, 2006Applicant: Pharma Pacific Pty Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Tovey
-
Publication number: 20060099174Abstract: The present disclosure relates to identification of genes upregulated by interferon-? administration, in particular the human genes corresponding to the cDNA sequences in GenBank designated g4586459, g2342476, g3327161 and g4529886. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the proteins encoded by the same genes is also envisaged.Type: ApplicationFiled: January 9, 2006Publication date: May 11, 2006Applicant: Pharma Pacific Pty Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Tovey
-
Publication number: 20050265967Abstract: The present invention relates to identification of a gene upregulated by interferon-administration corresponding to the cDNA sequence set forth in SEQ. ID. No. 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon- and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.Type: ApplicationFiled: August 8, 2003Publication date: December 1, 2005Applicant: Pharma Pacific Pty LtdInventors: Michel Dron, Jean-Francois Meritet, Michael Tovey
-
Publication number: 20050129657Abstract: The present invention relates to identification of a gene upregulated by interferon-? administration corresponding to the cDNA sequences set forth in SEQ. ID. No. 1 or in SEQ. ID. No. 3. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-? and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.Type: ApplicationFiled: November 8, 2004Publication date: June 16, 2005Applicant: Pharma Pacific Pty. Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Tovey
-
Publication number: 20040170961Abstract: The present invention relates to identification of a gene upregulated by interferon-administration corresponding to the cDNA sequence set forth in SEQ ID NO: 1. Determination of expression products of this gene is proposed as having utility in predicting responsiveness to treatment with interferon-&agr; and other interferons which act at the Type 1 interferon receptor. Therapeutic use of the protein encoded by the same gene is also envisaged.Type: ApplicationFiled: November 20, 2003Publication date: September 2, 2004Applicant: Pharma Pacific Pty. Ltd.Inventors: Jean-Francois Meritet, Michel Dron, Michael Gerard Tovey
-
Patent number: 6660258Abstract: Pharmaceutical compositions for oromucosal; contact to stimulate host defense mechanisms in a mammal, having an effective amount of Th1 or Th2 stimulating cytokine, and methods of treatment with such compositions are provided.Type: GrantFiled: October 9, 1998Date of Patent: December 9, 2003Assignee: Pharma Pacific Pty LtdInventor: Michael Gerard Tovey
-
Publication number: 20030108519Abstract: Interferon composition for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal with a stimulating amount of the interferon which exceeds parenterally administered amounts of interferon, methods of treatment with such compositions and uses of interferon in the preparation of such oromucosal compositions.Type: ApplicationFiled: December 30, 2002Publication date: June 12, 2003Applicant: Pharma Pacific Pty Ltd.Inventor: Michael Gerard Tovey
-
Patent number: 6361769Abstract: A method for stimulating host defense mechanisms in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon administered is less than an amount which induces a pathological response when administered parenterally.Type: GrantFiled: May 9, 1997Date of Patent: March 26, 2002Assignee: Pharma Pacific Pty LtdInventor: Michael Gerard Tovey
-
Patent number: 6207145Abstract: Interferon composition for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal with a stimulating amount of the interferon which exceeds parenterally administered amounts of interferon, methods of treatment with such compositions and uses of interferon in the preparation of such oromucosal compositions.Type: GrantFiled: May 9, 1997Date of Patent: March 27, 2001Assignee: Pharma Pacific Pty Ltd.Inventor: Michael Gerard Tovey
-
Patent number: 5997858Abstract: A method for treating neoplastic disease in a mammal via administering to the mammal a therapeutically effective amount of an interferon via oromucosal contact. The amount of interferon administered is less than an amount which induces a pathological response when administered parenterally.Type: GrantFiled: May 9, 1997Date of Patent: December 7, 1999Assignee: Pharma Pacific Pty Ltd.Inventors: Michael Gerard Tovey, Thomas James Kaido